Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $47.00 by Analysts at Robert W. Baird

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by research analysts at Robert W. Baird from $72.00 to $47.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Robert W. Baird’s price target points to a potential upside of 108.94% from the stock’s previous close.

Several other equities research analysts have also recently issued reports on the stock. Barclays lowered their price objective on shares of Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating for the company in a research report on Monday, November 24th. Wells Fargo & Company reduced their price objective on Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating on the stock in a report on Tuesday. TD Cowen lowered their target price on Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Leerink Partners lowered their price objective on shares of Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Tuesday. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, October 8th. Fifteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $75.19.

Ultragenyx Pharmaceutical Trading Up 14.1%

Shares of RARE stock traded up $2.78 on Tuesday, reaching $22.50. 5,898,943 shares of the company’s stock were exchanged, compared to its average volume of 1,462,417. The company’s fifty day simple moving average is $33.66 and its 200 day simple moving average is $32.11. Ultragenyx Pharmaceutical has a 52 week low of $18.41 and a 52 week high of $46.50. The stock has a market capitalization of $2.17 billion, a PE ratio of -3.76 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.58). Ultragenyx Pharmaceutical had a negative return on equity of 414.17% and a negative net margin of 91.95%.The business had revenue of $159.93 million during the quarter, compared to analysts’ expectations of $167.42 million. During the same quarter in the previous year, the business earned ($1.40) EPS. The business’s revenue for the quarter was up 14.6% on a year-over-year basis. As a group, sell-side analysts predict that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current fiscal year.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,942 shares of the firm’s stock in a transaction on Monday, October 13th. The shares were sold at an average price of $31.51, for a total value of $250,252.42. Following the completion of the transaction, the chief financial officer owned 98,227 shares of the company’s stock, valued at approximately $3,095,132.77. This trade represents a 7.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of RARE. Parallel Advisors LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 1,061.9% during the second quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 669 shares during the period. Assetmark Inc. boosted its holdings in shares of Ultragenyx Pharmaceutical by 1,706.7% in the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 1,024 shares during the last quarter. Huntington National Bank increased its stake in shares of Ultragenyx Pharmaceutical by 56.2% in the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 393 shares during the period. Danske Bank A S purchased a new position in shares of Ultragenyx Pharmaceutical during the third quarter worth $39,000. Finally, Smartleaf Asset Management LLC lifted its position in Ultragenyx Pharmaceutical by 205.4% during the third quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 1,169 shares during the period. 97.67% of the stock is owned by institutional investors and hedge funds.

Key Stores Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Analysts remain constructive despite cuts — Jefferies cut its target from $114 to $63 but kept a “Buy” rating; Wells Fargo cut its target from $65 to $45 but kept an “Overweight” rating. These retained positive ratings suggest some firms still see long‑term value or upside after the selloff. Benzinga
• Neutral Sentiment: Unusual options activity — investors bought 3,801 call contracts (≈+154% vs. average), which could reflect speculative bets on a rebound, hedging, or directional trading amid large share volatility. (No article link)
• Negative Sentiment: Phase 3 failure — Ultragenyx said neither Orbit nor Cosmic met the primary endpoint of reducing annualized clinical fracture rate vs. placebo or bisphosphonates, respectively; this is the direct clinical reason for the stock drop. Company Release
• Negative Sentiment: Immediate market impact — media reports and market wires show a sharp share plunge, a trading halt, and heavy volume as investors priced in the failed trials; the company lost a large portion of market value in short order. Reuters
• Negative Sentiment: Operational consequences — Ultragenyx signaled “significant” cutbacks following the failed study, which could reduce near‑term expenses but also reflects a re‑prioritization and potential delays to other programs. BizJournals

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.